Does an antibiotic stewardship programme reduce length of stay in children with asthma? A quality-improvement audit
Published
April 17, 2025
Paper ID
PAP-000275
Status
Published
DOI
10.65712/tmj.test000533
Advance Services
Abstract
Background: length of stay remains a leading cause of avoidable harm among children with asthma. Methods: The primary outcome was length of stay, assessed blind to allocation. Results: Effects were consistent across prespecified subgroups. Serious adverse events were rare and similar between groups. Conclusion: Strengths include the sample size and blinded outcome assessment.
Introduction
Earlier studies of an antibiotic stewardship programme were small or single-centre. length of stay remains a leading cause of avoidable harm among children with asthma. Guidelines make only a weak recommendation on an antibiotic stewardship programme.
The cost of length of stay to health systems is substantial. Guidelines make only a weak recommendation on an antibiotic stewardship programme. length of stay remains a leading cause of avoidable harm among children with asthma.
Earlier studies of an antibiotic stewardship programme were small or single-centre. length of stay remains a leading cause of avoidable harm among children with asthma.
Practice around an antibiotic stewardship programme varies widely between centres.
Discussion
Residual confounding cannot be excluded. Strengths include the sample size and blinded outcome assessment. These findings suggest that an antibiotic stewardship programme is associated with better length of stay in children with asthma.
Strengths include the sample size and blinded outcome assessment. Residual confounding cannot be excluded.
Strengths include the sample size and blinded outcome assessment. Implementation will depend on staffing, cost and local protocols. Residual confounding cannot be excluded. These findings suggest that an antibiotic stewardship programme is associated with better length of stay in children with asthma.
Strengths include the sample size and blinded outcome assessment. Residual confounding cannot be excluded.
Conclusions
An antibiotic stewardship programme is a reasonable option for children with asthma to improve length of stay.
References
1. Patel H, Mensah X, et al. An antibiotic stewardship programme and health-related quality of life. Crit Care Med. 2019;35(4):571-1039.
2. Rahman O, Volkov O, et al. Continuous glucose monitoring and surgical site infection. Diabetes Care. 2011;164(8):517-989.
3. Silva J, Rahman R, et al. Continuous glucose monitoring and 30-day readmission. N Engl J Med. 2014;222(1):647-1039.
4. Kowalski Z, Costa F, et al. An enhanced recovery pathway and post-operative delirium. Crit Care Med. 2024;99(2):551-1270.
5. Andersen G, Silva U, et al. Frailty screening and medication adherence. Pediatrics. 2012;326(8):284-1310.
6. Mueller K, Tanaka R, et al. Continuous glucose monitoring and emergency department revisits. BMJ. 2017;80(9):192-904.
7. Schmidt H, Ibrahim T, et al. Continuous glucose monitoring and glycaemic control. N Engl J Med. 2012;264(1):636-1539.
Appendices
The statistical analysis plan is in the online supplement.
Materials and Methods
Missing data were handled with multiple imputation. The primary outcome was length of stay, assessed blind to allocation. Eligible participants were children with asthma.
The primary outcome was length of stay, assessed blind to allocation. Eligible participants were children with asthma.
The primary outcome was length of stay, assessed blind to allocation. We conducted a quality-improvement audit across 12 centres between 2017 and 2021. Missing data were handled with multiple imputation. We conducted a quality-improvement audit across 14 centres between 2016 and 2025.
We conducted a quality-improvement audit across 10 centres between 2017 and 2025. The primary outcome was length of stay, assessed blind to allocation. Eligible participants were children with asthma.
Results
1719 participants were included (median age 36 years). Effects were consistent across prespecified subgroups. Serious adverse events were rare and similar between groups.
The adjusted odds ratio was 0.76 (95% CI 0.50 to 0.98). The adjusted odds ratio was 0.45 (95% CI 0.39 to 0.96). Serious adverse events were rare and similar between groups. length of stay occurred in 17% of the intervention group versus 28% of controls.
Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.84 (95% CI 0.38 to 0.88).
| Group | n | Events | Rate % | OR | 95% CI |
|---|---|---|---|---|---|
| Male | 321 | 73 | 9.1 | 0.49 | 0.47–1.38 |
| Centre A | 809 | 56 | 1.0 | 0.74 | 0.22–1.19 |
| Centre B | 744 | 100 | 9.5 | 0.42 | 0.60–1.9 |
| Male | 670 | 90 | 9.8 | 0.75 | 0.49–1.30 |
| Age ≥ 65 | 351 | 1 | 9.3 | 0.83 | 0.57–1.40 |
| Female | 295 | 67 | 35.7 | 0.85 | 0.40–1.15 |
Values are n (%) unless stated otherwise.

Shown for children with asthma; error bars are 95% confidence intervals.
Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.52 (95% CI 0.22 to 0.76).